Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

SOUTH SAN FRAN­CIS­CO — In 2020, Aviv Regev end­ed an es­teemed 14-year run at the Broad In­sti­tute to jump in­to the drug in­dus­try, be­com­ing Genen­tech’s head of re­search and ear­ly de­vel­op­ment.

The 52-year-old com­pu­ta­tion­al bi­ol­o­gist has pi­o­neered the field of sin­gle-cell ge­nomics, which stud­ies in­di­vid­ual cells at mas­sive scale, weav­ing to­geth­er bi­ol­o­gy and com­put­er sci­ence. Now, Regev is build­ing what she calls the “lab in a loop” at Genen­tech, where ex­per­i­men­tal and com­pu­ta­tion­al sci­en­tists train and work along­side each oth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER